DEPAKOTE Drug Patent Profile
✉ Email this page to a colleague
When do Depakote patents expire, and what generic alternatives are available?
Depakote is a drug marketed by Abbvie and Abbott and is included in four NDAs.
The generic ingredient in DEPAKOTE is divalproex sodium. There are eighteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depakote
A generic version of DEPAKOTE was approved as divalproex sodium by APOTEX on July 29th, 2008.
Summary for DEPAKOTE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Clinical Trials: | 97 |
| Patent Applications: | 4,850 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DEPAKOTE |
| Drug Sales Revenues: | Drug sales revenues for DEPAKOTE |
| What excipients (inactive ingredients) are in DEPAKOTE? | DEPAKOTE excipients list |
| DailyMed Link: | DEPAKOTE at DailyMed |
Recent Clinical Trials for DEPAKOTE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Virginia Commonwealth University | Phase 1/Phase 2 |
| Puma Biotechnology, Inc. | Phase 1/Phase 2 |
| Barretos Cancer Hospital | Early Phase 1 |
Pharmacology for DEPAKOTE
| Drug Class | Anti-epileptic Agent Mood Stabilizer |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for DEPAKOTE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | DEPAKOTE | divalproex sodium | CAPSULE, DELAYED REL PELLETS;ORAL | 019680-001 | Sep 12, 1989 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | DEPAKOTE ER | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 021168-002 | May 31, 2002 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | DEPAKOTE | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 018723-002 | Mar 10, 1983 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | DEPAKOTE ER | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 021168-001 | Aug 4, 2000 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DEPAKOTE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | DEPAKOTE | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 018723-002 | Mar 10, 1983 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | DEPAKOTE | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 018723-003 | Oct 26, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | DEPAKOTE | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 018723-003 | Oct 26, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | DEPAKOTE | divalproex sodium | CAPSULE, DELAYED REL PELLETS;ORAL | 019680-001 | Sep 12, 1989 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DEPAKOTE
See the table below for patents covering DEPAKOTE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 8100562 | ⤷ Try a Trial | |
| Germany | 3063328 | ⤷ Try a Trial | |
| Canada | 1136151 | SEL MIXTE D'ACIDE VALPROIQUE (MIXED SALT OF VALPROIC ACID) | ⤷ Try a Trial |
| Italy | 8024207 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
